Newsletter

Newsletter July 2018

There are many who show great interest for Cyxone and our drug candidates. We are pleased about the discussions happening around the effects of T20K and Rabeximod and what it can lead to in the future. Since there seems to be a lot that should be commented and explained, we would like to provide both […]

Read More

Newsletter April 2018

We are right in the middle of an exciting period for Cyxone with a lot of moving pieces and I get a lot of questions from shareholders that I would like to answer, but I am not always able to for different reasons. Our biggest focus in the recent months has been to finalize the […]

Read More

Newsletter February 2018

I once read a comment from a Cyxone shareholder that said the less the company communicates, the more we are getting done. With this newsletter, I want to prove that statement accurate! In recent months, Cyxone has focused on two key activities: the tests necessary to bring T20K for multiple sclerosis to clinical trials during […]

Read More

Newsletter January 2018

CEO’s comments 2017 was an exceptional year for Cyxone. In addition to running our original project – T20K for multiple sclerosis – we made progress in obtaining a clinical license for Rabeximod, a treatment for rheumatoid arthritis, for which we are in the process of planning a Phase 2B clinical trial. On top of all […]

Read More

Newsletter 1 December 2017

Extraordinary General Meeting and new directed share issue to take Rabeximod through Phase 2B trials Prior to the extraordinary general meeting (EGM) that will be held in Malmö on December 11, at 10AM, I would first like to thank shareholders for their considerable interest in participating in the EGM. As you may already know, we […]

Read More